Sarafan ChEM-H
Showing 1-50 of 66 Results
-
Bria Castellano
Scientific Program Manager, Sarafan ChEM-H
Current Role at StanfordSarafan ChEM-H* Scientific Program Manager
*Chemistry, Engineering and Medicine for Human Health Research Institute -
Thomas J Cirino
Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioIn Vivo Pharmacologist with expertise in CNS disorders including neurodegenerative disease, psychiatric disorders and pain.
-
Jean Dam
Research Scientist, Medicinal Chemistry, Innovative Medicines Accelerator (IMA)
Current Role at StanfordResearch Scientist at the MCKC
-
Marc Fleischmann
Project & Knowledge Management, Sarafan ChEM-H
Current Role at StanfordSolutions Wizard
-
Lynette Renae Haberman
Program Manager, Student Programs and Training, Sarafan ChEM-H
Current Role at StanfordProgram Manager, Student Programs and Training
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
-
Amy Jacobson
Director of Microbiome Therapies, Microbiome Therapies Initiative (MITI)
Current Role at StanfordSenior Scientific Program Manager, Sarafan ChEM-H and Stanford Innovative Medicines Accelerator
-
Pallavi Kompella
Lead Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioPh.D. Pharmaceutical Sciences, The University of Texas at Austin, Texas
(American Foundation for Pharmaceutical Education Doctoral Fellow)
Fulbright Postdoctoral Scholar, Biomedical Research Institute of Malaga, Spain -
Elizabeth Ponder
Executive Director, Sarafan ChEM-H
BioDr. Elizabeth Ponder joined Stanford ChEM-H in 2014 and is currently the Executive Director of Sarafan ChEM-H and the Stanford Innovative Medicines Accelerator (IMA). Dr. Ponder completed her Ph.D. and postdoctoral training at Stanford University in the laboratory of Dr. Matthew Bogyo. Her past work has included promoting public-private partnerships in the non-profit sector, managing multidisciplinary research in the higher education sector, and business development consulting in the for-profit biotech sector. Dr. Ponder joined ChEM-H from the University of California, Berkeley where she served as the Executive Director of the Henry Wheeler Center for Emerging & Neglected Diseases (CEND).
